BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Citi upgrades Cadila Healthcare to neutral
Citi upgrades Cadila to "neutral" from "sell" earlier. See limited downside in the stock. US execution key to sustained upside. Decrease FY17 earnings per share estimates by 16 per cent. Aurobindo remains top pick in the sector.